Skip to main
ENGN

ENGN Stock Forecast & Price Target

ENGN Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 14%
Buy 71%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

enGene Holdings Inc. is positioned favorably within the biotechnology sector, particularly due to the successful advancement of its non-viral gene therapy, detalimogene, which has received RMAT designation, indicating potential for expedited development in addressing non-muscle invasive bladder cancer. The company's recent protocol amendments have shown a significant impact on the six-month complete response (CR) rates, aligning them with best-in-class competitors while maintaining an overall superior profile due to its non-viral approach. With research and development expenses rising as the company intensifies its focus on manufacturing and clinical trial costs, enGene's progression in the LEGEND study and potential expansion of its target market are likely to support a positive financial outlook.

Bears say

enGene Holdings Inc. faces a negative outlook due to disappointing performance in its ongoing LEGEND trial, coupled with unexpected safety issues that could undermine investor confidence. Changes in regulatory requirements for non-muscle invasive bladder cancer (NMIBC) approvals and the emergence of unforeseen competition add further pressure, potentially delaying market entry and approval timelines that are critical for the company’s viability. Additionally, the necessity for higher-than-expected capital, likely leading to equity dilution, raises financial risks for existing shareholders as the company may need to pursue secondary offerings to fund its drug development initiatives.

ENGN has been analyzed by 7 analysts, with a consensus rating of Buy. 14% of analysts recommend a Strong Buy, 71% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Engene Holdings Inc (ENGN) Forecast

Analysts have given ENGN a Buy based on their latest research and market trends.

According to 7 analysts, ENGN has a Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Engene Holdings Inc (ENGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.